Medroxyprogesterone, a common progestational agent, has been shown to produce a hypercoagulable state in high dosages. . Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly. My girl friend is on her 150 mcg levothyroxine and is on her first Depo-Provera provera (medroxyprogesterone) shot. The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years. Free T3 resin uptake may be decreased. Applies to: OsteoporosisThe use of intramuscular medroxyprogesterone for contraception has been shown to induce bone loss, particularly during the early years of therapy. Applies to: ObesityProgestogens can cause weight gain, which may be significant (as is the case with parenteral medroxyprogesterone) and undesirable in obese patients attempting to lose weight.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Pharmacia and Upjohn, Kalamazoo, MI. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer."

Manage your drugs with real-world data: Changes have mostly been reported with the use of combination oral contraceptives. Back to Top. Dr. Nela Cordero answered Applies to: Thyroid DiseaseWhen administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests. Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.Major Potential Hazard, Moderate plausibility. There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease. Applies to: HyperlipidemiaSome progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent. Some reports may have incomplete information.Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. Therapy with parenteral medroxyprogesterone should be administered cautiously in patients with osteoporosis or chronic use of drugs that can reduce bone mass, such as anticonvulsants or corticosteroids.Major Potential Hazard, Moderate plausibility. Drug interactions are reported among people who take Depo-provera and Levothyroxine sodium together. Applies to: Renal Dysfunction, Migraine, Congestive Heart Failure, Asthma, Fluid Retention, Seizures, HypertensionEstrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods. The study is created by eHealthMe based on reports of 53 people who take Depo-provera and Levothyroxine sodium from the FDA, and is updated regularly. Drug interactions are reported among people who take Depo-provera and Levothyroxine sodium together. However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver. Applies to: Visual Defect/DisturbanceEstrogens and progestogens may cause retinal thrombosis.

How it works. Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely. Levothyroxine is a man-made form of thyroxine, a hormone that is produced naturally … Some supportive data are available for medroxyprogesterone. A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate. I am also taking synthroid for thyroid problems. And many women have written to me questioning if the birth control pill could be sabotaging their thyroid health. Applies to: Abnormal Uterine BleedingThe use of medroxyprogesterone in women with undiagnosed vaginal bleeding is contraindicated. Altered menstrual bleeding patterns include amenorrhea, irregular or unpredictable bleeding or spotting, prolonged spotting or bleeding, and heavy bleeding. Applies to: Abnormal Uterine BleedingThe use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding. A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.Major Potential Hazard, High plausibility. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.Major Potential Hazard, High plausibility. Provera & Synthroid. However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent. The birth control and thyroid connection is real! However, thrombophlebitis and pulmonary embolism have been reported with megestrol, an antineoplastic and progestational agent.